29655-46-7

Basic information

• Product Name: Benzyl N-[2-(4-hydroxyphenyl)ethyl]carbamate
• Synonyms: Benzyl N-[2-(4-hydroxyphenyl)ethyl]carbamate
• CAS NO: 29655-46-7
• Molecular Formula: C₁₆H₁₇NO₃
• Molecular Weight: 271.31108
• Mol File: 29655-46-7.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Benzyl N-[2-(4-hydroxyphenyl)ethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: Benzyl N-[2-(4-hydroxyphenyl)ethyl]carbamate(29655-46-7)
• EPA Substance Registry System: Benzyl N-[2-(4-hydroxyphenyl)ethyl]carbamate(29655-46-7)

Safety Data

• Hazardous Substances Data: 29655-46-7(Hazardous Substances Data)

Usage

General Description

Benzyl N-[2-(4-hydroxyphenyl)ethyl]carbamate, also known as U-50488, is a synthetic opioid analgesic drug with strong analgesic effects similar to those of morphine. It is a kappa opioid receptor agonist and has been used in scientific research to study the kappa opioid receptor and its role in various physiological and psychological processes. However, its potential for abuse and dependence has limited its use as a pain medication, and it is classified as a Schedule I controlled substance in the United States. Research on its potential therapeutic applications and mechanisms of action are ongoing in the fields of pharmacology and neuroscience.

Upstream product

• 51-67-2 tyrosamine 
• 501-53-1 benzyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 1164-16-5 Z-L-Tyr-OH 
• 1067665-51-3 benzyl (4-(benzyloxy)phenethyl)carbamate 
• 60-19-5 tyramine hydrochloride 

Downstream Products

• 873998-55-1 (4-dimethylcarbamoyloxy-phenethyl)-carbamic acid benzyl ester 
• 70468-82-5 {4-[2-methyl-1-(2-oxo-oxazolidin-4-yl)-propoxy]-phenethyl}-carbamic acid benzyl ester 
• 146399-65-7 4-<2-(benzyloxycarbonylamino)ethyl>phenyl 3-O-acetyl-2,4-di-O-methyl-α-L-rhamnopyranoside 
• 174360-05-5 {2-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-ethyl}-carbamic acid benzyl ester 
• 221357-20-6 [2-(4-tert-butoxy-phenyl)-ethyl]-carbamic acid benzyl ester 
• 245078-44-8 N,N-diethyl-2-(4-(2-N-benzyloxycarbamyllethyl)phenoxy)acetamide 
• 257294-53-4 4-[2-(benzyloxycarbonylamino)-ethyl]phenyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranoside 
• 46843-08-7 N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)ethylamine 
• 133025-92-0 N,N-diethyl-2-(4-(2-aminoethyl)phenoxy)acetamide 
• 157981-64-1 2-(4-tert-butyloxyphenyl)ethylamine 
• 55458-78-1 2-<4-(2-aminoethyl)phenoxy>-2-methylpropionic acid 
• 174360-06-6 2-[4-(2-Methoxy-ethoxymethoxy)-phenyl]-ethylamine 
• 174360-16-8 [Isopropyl-(2-{2-[4-(2-methoxy-ethoxymethoxy)-phenyl]-ethylamino}-acetyl)-amino]-acetic acid tert-butyl ester 
• 174360-17-9 {[2-((2-Bromo-acetyl)-{2-[4-(2-methoxy-ethoxymethoxy)-phenyl]-ethyl}-amino)-acetyl]-isopropyl-amino}-acetic acid tert-butyl ester 

Relevant articles and documents

Insulin Analogues with Altered Insulin Receptor Isoform Binding Specificities and Enhanced Aggregation Stabilities

Insulin is a lifesaver for millions of diabetic patients. There is a need for new insulin analogues with more physiological profiles and analogues that will be thermally more stable than human insulin. Here, we describe the chemical engineering of 48 insulin analogues that were designed to have changed binding specificities toward isoforms A and B of the insulin receptor (IR-A and IR-B). We systematically modified insulin at the C-terminus of the B-chain, at the N-terminus of the A-chain, and at A14 and A18 positions. We discovered an insulin analogue that has Cα-carboxyamidated Glu at B31 and Ala at B29 and that has a more than 3-fold-enhanced binding specificity in favor of the "metabolic"IR-B isoform. The analogue is more resistant to the formation of insulin fibrils at 37 °C and is also more efficient in mice than human insulin. Therefore, [AlaB29,GluB31,amideB31]-insulin may be interesting for further clinical evaluation.

Chemical Synthesis of the Trisaccharide Epitope of Phenolic Glycolipid-1 Surface Antigen from Mycobacterium leprae

PGL-1 epitope 1 bearing a p-aminoethylphenol group was efficiently synthesized by using linear synthetic routes. A method for efficient synthesis of oligosaccharides containing rhamnose rings was developed. The chemistry is flexible and could be used for

GLYCOPOLYMERS SEQUESTERING CARBOHYDRATE-BINDING PROTEINS

The invention relates to polymers comprising carbohydrate ligands and moieties, respectively, that bind to carbohydrate-binding proteins (CBPs), as well as to these carbohydrate ligands, and to their use in diagnosis and therapy of diseases that are assoc